BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 4月 2025 15:01:00 条件 Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

31 3月 2025 15:10:00 条件 Nasdaq GlobeNewswire

Biomea Fusion Announces Leadership Transition

25 3月 2025 18:00:00 条件 Nasdaq GlobeNewswire

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

24 3月 2025 07:30:00 条件 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 3月 2025 07:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

27 2月 2025 07:00:01 条件 Nasdaq GlobeNewswire

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

13 1月 2025 08:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

07 1月 2025 08:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1月 2025 06:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

17 12月 2024 07:10:00 条件 Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

16 12月 2024 17:15:01 条件 Nasdaq GlobeNewswire

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

12 12月 2024 16:02:21 条件 Nasdaq GlobeNewswire

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

09 12月 2024 15:01:00 条件 Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

06 12月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

02 12月 2024 15:05:00 条件 Nasdaq GlobeNewswire

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

18 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 11月 2024 15:05:51 条件 Nasdaq GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30 10月 2024 15:00:48 条件 Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

29 10月 2024 15:46:08 条件 Nasdaq GlobeNewswire

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

21 10月 2024 08:00:29 条件 Nasdaq GlobeNewswire